The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies
Open accessAbstract
BACKGROUND: Controversy persists about optimal mammography screening strategies. OBJECTIVE: To evaluate screening outcomes, taking into account advances in mammography and treatment of breast cancer. DESIGN: Collaboration of 6 simulation models using national data on incidence, digital mammography performance, treatment effects, and other-cause mortality. SETTING: United States. PATIENTS: Average-risk U.S. female population and subgroups with varying risk, breast density, or comorbidity. INTERVENTION: Eight strategies differing by age at which screening starts (40, 45, or 50 years) and screening interval (annual, biennial, and hybrid [annual for women in their 40s and biennial thereafter]). All strategies assumed 100% adherence and stopped at age 74 years. MEASUREMENTS: Benefits (breast cancer-specific mortality reduction, breast cancer deaths averted, life-years, and quality-adjusted life-years); number of mammograms used; harms (false-positive results, benign biopsies, and overdiagnosis); and ratios of harms (or use) and benefits (efficiency) per 1000 screens. RESULTS: Biennial strategies were consistently the most efficient for average-risk women. Biennial screening from age 50 to 74 years avoided a median of 7 breast cancer deaths versus no screening; annual screening from age 40 to 74 years avoided an additional 3 deaths, but yielded 1988 more false-positive results and 11 more overdiagnoses per 1000 women screened. Annual screening from age 50 to 74 years was inefficient (similar benefits, but more harms than other strategies). For groups with a 2- to 4-fold increased risk, annual screening from age 40 years had similar harms and benefits as screening average-risk women biennially from 50 to 74 years. For groups with moderate or severe comorbidity, screening could stop at age 66 to 68 years. LIMITATION: Other imaging technologies, polygenic risk, and nonadherence were not considered. CONCLUSION: Biennial screening for breast cancer is efficient for average-risk populations. Decisions about starting ages and intervals will depend on population characteristics and the decision makers' weight given to the harms and benefits of screening. PRIMARY FUNDING SOURCE: National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammographic Density and the Risk and Detection of Breast Cancer
Boyd, N. F., Guo, H., Martin, L. J., Sun, L., Stone, J., Fishell, E., Jong, R. A., Hislop, G., Chiarelli, A., Minkin, S., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062790 · Cited by 2,478
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Self-citationScreening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening
Pisano, E. D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J. K., Acharyya, S., Conant, E. F., Fajardo, L. L., Bassett, L., D'Orsi, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052911 · Cited by 1,940
Screening for breast cancer with mammography
Gøtzsche, P. C., & Jørgensen, K. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001877.pub5 · Cited by 1,869
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00008 · Cited by 1,686
Long-term effects of mammography screening: updated overview of the Swedish randomised trials
Nyström, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjöld, B., & Rutqvist, L. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08020-0 · Cited by 1,183
Cancer Screening in Elderly Patients: A Framework for Individualized Decision Making
Walter, L. C., & Covinsky, K. E. (2001) · JAMA · doi:10.1001/jama.285.21.2750 · Cited by 1,003
Breast-Cancer Screening — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., & Straif, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1504363 · Cited by 962
Cited by
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00008 · Cited by 1,686
Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
Bakker, M. F., de Lange, S. V., Pijnappel, R. M., Mann, R. M., Peeters, P. H. M., Monninkhof, E. M., Emaus, M. J., Loo, C. E., Bisschops, R. H. C., Lobbes, M. B. I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903986 · Cited by 702
Self-citationKnudsen, A. B., Zauber, A. G., Rutter, C. M., Naber, S. K., Doria-Rose, V. P., Pabiniak, C., Johanson, C., Fischer, S. E., Lansdorp-Vogelaar, I., & Kuntz, K. M. (2016) · JAMA · doi:10.1001/jama.2016.6828 · Cited by 474
Brozek, J. L., Canelo-Aybar, C., Akl, E. A., Bowen, J. M., Bucher, J., Chiu, W. A., Cronin, M., Djulbegovic, B., Falavigna, M., Guyatt, G. H., et al. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.09.018 · Cited by 331
Metadata
- Authors
- Mandelblatt, J. S., Stout, N. K., Schechter, C. B., van den Broek, J. J., Miglioretti, D. L., Krapcho, M., Trentham-Dietz, A., Munoz, D., Lee, S. J., Berry, D. A., van Ravesteyn, N. T., Alagoz, O., Kerlikowske, K., Tosteson, A. N. A., Near, A. M., Hoeffken, A., Chang, Y., Heijnsdijk, E. A., Chisholm, G., Huang, X., Huang, H., Ergun, M. A., Gangnon, R., Sprague, B. L., Plevritis, S., Feuer, E., de Koning, H. J., & Cronin, K. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-02-16
- Volume
- 164
- Issue
- 4
- Pages
- 215-225
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2282197435
- Cited by
- 281
- References
- 64
- FWCI
- 16.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. https://app.cochat.ai/papers/10.7326/m15-1536
- The paper
- Mandelblatt, J. S., Stout, N. K., Schechter, C. B., van den Broek, J. J., Miglioretti, D. L., Krapcho, M., Trentham-Dietz, A., Munoz, D., Lee, S. J., Berry, D. A., van Ravesteyn, N. T., Alagoz, O., Kerlikowske, K., Tosteson, A. N. A., Near, A. M., Hoeffken, A., Chang, Y., Heijnsdijk, E. A., Chisholm, G., . . . Cronin, K. A. (2016). Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine. https://doi.org/10.7326/m15-1536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.